Skip to main content

Vertex Pharmaceuticals



) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1%. By the end of trading, Vertex Pharmaceuticals rose $1.19 (2%) to $59.62 on light volume. Throughout the day, 1.3 million shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 3.9 million shares. The stock ranged in a price between $58.43-$60 after having opened the day at $58.80 as compared to the previous trading day's close of $58.43. Other companies within the Drugs industry that increased today were:

Supernus Pharmaceuticals



), up 114.2%,

Aoxing Pharmaceutical Company



), up 24.6%,




), up 19.7%, and

TheStreet Recommends




), up 19%.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. Vertex Pharmaceuticals has a market cap of $12.79 billion and is part of the

health care

sector. The company has a P/E ratio of 41.8, below the average drugs industry P/E ratio of 44.2 and above the S&P 500 P/E ratio of 17.7. Shares are up 82.5% year to date as of the close of trading on Monday. Currently there are 12 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front,

Prima Biomed Ltd. ADR



), down 22.1%,




), down 20.3%,




), down 11.8%, and

Celsion Corporation



), down 9.3%, were all losers within the drugs industry with




) being today's drugs industry loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech